Enanta Pharmaceuticals Inc
NASDAQ:ENTA
Enanta Pharmaceuticals Inc
Revenue
Enanta Pharmaceuticals Inc
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Enanta Pharmaceuticals Inc
NASDAQ:ENTA
|
Revenue
$73.6m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
31%
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$54.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$27.5B
|
CAGR 3-Years
2%
|
CAGR 5-Years
4%
|
CAGR 10-Years
7%
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$28.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$9.9B
|
CAGR 3-Years
17%
|
CAGR 5-Years
26%
|
CAGR 10-Years
23%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$13.1B
|
CAGR 3-Years
16%
|
CAGR 5-Years
14%
|
CAGR 10-Years
20%
|
Enanta Pharmaceuticals Inc
Revenue Breakdown
Breakdown by Geography
Enanta Pharmaceuticals Inc
Breakdown by Segments
Enanta Pharmaceuticals Inc
Total Revenue:
79.2m
USD
|
Royalty:
78.2m
USD
|
License:
1m
USD
|
See Also
What is Enanta Pharmaceuticals Inc's Revenue?
Revenue
73.6m
USD
Based on the financial report for Dec 31, 2023, Enanta Pharmaceuticals Inc's Revenue amounts to 73.6m USD.
What is Enanta Pharmaceuticals Inc's Revenue growth rate?
Revenue CAGR 10Y
31%
Over the last year, the Revenue growth was -10%. The average annual Revenue growth rates for Enanta Pharmaceuticals Inc have been -10% over the past three years , -21% over the past five years , and 31% over the past ten years .